Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 May 23;92(10):1862-8.
doi: 10.1038/sj.bjc.6602590.

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

T F Greten  1 , F Papendorf, J S Bleck, T Kirchhoff, T Wohlberedt, S Kubicka, J Klempnauer, M Galanski, M P Manns
Affiliations

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

T F Greten et al. Br J Cancer. .

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. However, treatment options are limited and often inefficient. The aim of this study was to determine current survival rates for patients diagnosed with HCC and to identify prognostic factors, which will help in choosing optimal therapies for individual patients. A retrospective analysis of medical records was performed on 389 patients who were identified through the central tumour registry at our institution from 1998 to 2003. Clinical parameters, treatments received and survival curves from time of diagnosis were analysed. Overall median survival was 11 months. Liver cirrhosis was diagnosed in 80.5% of all patients. A total of 170 patients received transarterial chemoembolisation (TACE) and/or percutaneous ethanol injections (PEI) with a median survival rate of 16 months for patients receiving TACE, 11 months for patients receiving PEI and 24 months for patients receiving TACE followed by PEI. Independent negative prognostic parameters for survival were the presence of portal vein thrombosis, advanced liver cirrhosis (Child-Pugh score B or C) and a score of >2. This study will help to estimate survival rates for patients with HCC according to their clinical status at diagnosis and the treatments received.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment algorithm for patients with HCC.
Figure 2
Figure 2
Kaplan–Meier survival curve for all 389 patients. Median survival rate was 13 months, 1- and 3-year survival rate at 53 and 22 months. Median survival is presented as month (upper – lower interquartile range).
Figure 3
Figure 3
Kaplan–Meier survival curve for 355 patients depending on the presence and extent of liver cirrhosis according to Child–Pugh classification. Median survival is presented as month (upper – lower interquartile range).
Figure 4
Figure 4
Kaplan–Meier survival curve for 240 patients depending on their initial CLIP score. Median survival is presented as month (upper – lower interquartile range).
Figure 5
Figure 5
Kaplan–Meier survival curve for 341patients depending on the presence (+) or absence (−) of a portal vein thrombosis. Median survival is presented as month (upper – lower interquartile range).
Figure 6
Figure 6
Kaplan–Meier survival curve for 288 patients depending on the therapy received. Median survival is presented as month (upper – lower interquartile range).
See this image and copyright information in PMC

References

    1. Allgaier HP, Deibert P, Olschewski M, Spamer C, Blum U, Gerok W, Blum HE (1998) Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection – a single-center analysis including 132 patients. Int J Cancer 79: 601–605 - PubMed
    1. Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5–S16 - PubMed
    1. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35: 519–524 - PubMed
    1. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421–430 - PubMed
    1. Caselitz M, Masche N, Flemming P, Stern C, Manns MP, Wagner S, Kubicka S (2004) Prognosis of hepatocellular carcinoma according to new staging systems. Dtsch Med Wochenschr 129: 1725–1730 - PubMed

Publication types

MeSH terms